Every S-3 that ADC Therapeutics SA (ADCT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
ADC Therapeutics is filing a resale registration to permit the selling shareholders to offer up to 9,834,776 common shares issuable upon exercise of warrants.
The prospectus states the company is not selling any shares here and will not receive proceeds from resale transactions. If the warrants are exercised for cash, the company may receive up to $37.5 million, to be used for working capital and general corporate purposes. The warrants were issued to HCR on February 18, 2026, have an exercise price of $3.8130 per share, are exercisable until December 31, 2030, and are not transferable on or prior to December 31, 2027.
ADC Therapeutics SA filed Amendment No. 1 to its shelf registration statement as an exhibit-only update to include a new auditor consent from PricewaterhouseCoopers SA. The company states that this amendment does not change any part of the prospectus and consists only of the facing page, an explanatory note, Part II, signatures, the exhibit index and the new exhibit.
The company estimates total offering-related expenses of $71,341.46, including a SEC registration fee of $8,341.46, legal and accounting fees and printing costs. ADC Therapeutics will bear its own registration expenses, while any selling shareholders would be responsible for brokerage commissions or similar charges if they sell shares under the registration. The filing also restates standard Swiss-law based indemnification provisions for directors and officers and includes customary Securities Act undertakings.
ADC Therapeutics SA filed a resale registration allowing selling shareholders to offer up to 14,696,253 common shares from time to time as described under “Plan of Distribution.” The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling shareholders.
The filing covers shares issued in an October 2025 private placement, specifically 10,850,100 common shares and 3,846,153 common shares issuable upon exercise of pre-funded warrants. If those pre-funded warrants are exercised in cash, the company may receive up to CHF 307,692, earmarked for working capital and general corporate purposes. ADC Therapeutics’ common shares trade on the NYSE under the symbol ADCT.